Rhythm Pharmaceuticals 미래 성장

Future 기준 확인 5/6

Rhythm Pharmaceuticals (는) 각각 연간 65.4% 및 43.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 65.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -92.6% 로 예상됩니다.

주요 정보

65.4%

수익 성장률

65.18%

EPS 성장률

Biotechs 수익 성장	23.9%
매출 성장률	43.6%
향후 자기자본 수익률	-92.56%
애널리스트 커버리지	Good
마지막 업데이트	15 May 2025

최근 미래 성장 업데이트

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Recent updates

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

May 04

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

수익 및 매출 성장 예측

NasdaqGM:RYTM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	552	113	59	145	8
12/31/2026	304	-88	-104	-17	12
12/31/2025	175	-171	-176	-143	12
3/31/2025	137	-174	-114	-113	N/A
12/31/2024	130	-265	-154	-114	N/A
9/30/2024	113	-262	-165	-124	N/A
6/30/2024	102	-261	-169	-128	N/A
3/31/2024	92	-274	-182	-140	N/A
12/31/2023	77	-185	-142	-136	N/A
9/30/2023	62	-186	-146	-141	N/A
6/30/2023	44	-182	-164	-159	N/A
3/31/2023	34	-181	-161	-156	N/A
12/31/2022	24	-181	-174	-173	N/A
9/30/2022	17	-181	-173	-180	N/A
6/30/2022	13	-176	-166	-173	N/A
3/31/2022	5	-166	-160	-166	N/A
12/31/2021	3	-70	-139	-146	N/A
9/30/2021	1	-62	-135	-135	N/A
6/30/2021	0	-60	-122	-122	N/A
3/31/2021	0	-56	-120	-119	N/A
12/31/2020	N/A	-134	-122	-122	N/A
9/30/2020	N/A	-132	-125	-125	N/A
6/30/2020	N/A	-134	-132	-132	N/A
3/31/2020	N/A	-146	-130	-127	N/A
12/31/2019	N/A	-141	-126	-123	N/A
9/30/2019	N/A	-133	-115	-112	N/A
6/30/2019	N/A	-115	-99	-95	N/A
3/31/2019	N/A	-87	-83	-82	N/A
12/31/2018	N/A	-74	N/A	-62	N/A
9/30/2018	N/A	-59	N/A	-49	N/A
6/30/2018	N/A	-53	N/A	-40	N/A
3/31/2018	N/A	-47	N/A	-34	N/A
12/31/2017	N/A	-38	N/A	-29	N/A
9/30/2017	N/A	-36	N/A	-28	N/A
6/30/2017	N/A	-32	N/A	-24	N/A
3/31/2017	N/A	-30	N/A	-24	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-21	N/A
6/30/2016	N/A	-23	N/A	-18	N/A
3/31/2016	N/A	-17	N/A	-13	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-3	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-6	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RYTM 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.8% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: RYTM (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: RYTM 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: RYTM 의 수익(연간 43.6% ) US 시장( 8.5% 보다 빠르게 성장할 것으로 예상됩니다. 8.5% 연간).

고성장 수익: RYTM 의 수익(연간 43.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RYTM (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/18 20:08
장 마감 주가	2025/05/16 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Rhythm Pharmaceuticals, Inc. 20 애널리스트 중 12 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Tazeen Ahmad	BofA Global Research
Whitney Ijem	Canaccord Genuity
Jonathan Wolleben	Citizens JMP Securities, LLC

Rhythm Pharmaceuticals 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Recent updates

Rhythm Pharmaceuticals, Inc. Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for Up to Nine Months in French Early-access Program

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

Rhythm Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint with -19.8%

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2025

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Rhythm Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals: A Key Year Ahead

Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Executive VP & Head of North America exercised options and sold US$180k worth of stock

Executive VP & Head of North America notifies of intention to sell stock

Consensus revenue estimates increase by 28%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 19%

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023